New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:00 EDTALXNAlexion initiates voluntary recall of certain lots of Soliris
Alexion Pharmaceuticals announced that it is initiating a voluntary recall of certain lots of Soliris 300 mg/30 mL concentrated solution for intravenous infusion that were manufactured using a process component during vial filling identified in the November 2013 recall to the hospital/user level. As previously stated, Alexion believes that it has identified the process component that resulted in the presence of the visible particles and implemented a change to the process. Alexion does not anticipate any interruption to patient supply. This recall has been initiated due to the presence of visible proteinaceous particles detected in a single lot during periodic stability testing for Soliris. This lot was distributed only in the U.S. No safety risks to patients who have received Soliris have been identified. There is no financial impact from the voluntary recall. Following this voluntary recall, there will no longer be Soliris in the U.S. manufactured using the previously identified process component that Alexion believes resulted in the stability failure.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
07:13 EDTALXNAlexion receives CHMP positive opinions for Strensiq, Kanuma in the EU
Subscribe for More Information
June 23, 2015
06:32 EDTALXNAlexion completes acquisition of Synageva
Subscribe for More Information
June 22, 2015
06:33 EDTALXNAlexion accepts shares of Synageva tendered into exchange offer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use